High Court Won't Weigh Suit Over Generic Reglan Labeling

Law360, New York (April 30, 2012, 7:27 PM EDT) -- The U.S. Supreme Court on Monday declined to hear an appeal of a Sixth Circuit ruling dismissing three failure-to-warn suits targeting Barr Pharmaceuticals and other drugmakers over generic versions of heartburn medication Reglan.

Rejecting a petition for writ of certiorari filed in February, the high court cemented the Sixth Circuit ruling, which cited last year's Supreme Court decision in Pliva Inc. v. Mensing in throwing out the suits. That ruling held that state law tort claims against generics makers are preempted because the Hatch-Waxman amendments require...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.